Pharma BD Deal Intelligence
Loxo got $400M upfront from Bayer for a 50/50 split of larotrectinib and LOXO-195, and the TRK inhibitor later won approval as Vitrakvi — though Loxo's own shares dipped 6% on the news, with analysts questioning ceding U.S. commercial rights.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Loxo's shares dipped 6% in premarket trading as analysts questioned the wisdom of giving up US rights to larotrectinib, which was expected to spearhead Loxo's…
The Bayer-Loxo partnership was framed as the leading commercial vehicle for tissue-agnostic precision oncology following ASCO data showing durable activity…
After Lilly's $8B acquisition of Loxo, Bayer secured full global rights to Vitrakvi and BAY 2731954 (LOXO-195), consolidating control of the tissue-agnostic…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Loxo Oncology and Bayer announced a global co-development and co-commercialization partnership for the selective TRK inhibitors larotrectinib and LOXO-195. Loxo received $400M upfront plus up to $450M in larotrectinib milestones and $200M in LOXO-195 milestones (~$1.55B total). 50/50 global development cost split; Loxo leads U.S. regulatory; Bayer leads ex-U.S. regulatory and commercialization. 50/50 U.S. profit share. Larotrectinib later approved as Vitrakvi.
Assessment window: 5yr post-close.
2K US cases/yr
TRK fusion cancers arise from chromosomal rearrangements involving NTRK1/2/3 genes that produce constitutively active TRK kinases driving tumor growth. Fusions are rare overall (<1% of common adult cancers) but enriched in pediatric and rare adult tumors such as infantile fibrosarcoma and secretory breast carcinoma. Identification requires molecular testing (NGS, IHC, FISH), making diagnostic infrastructure the rate-limiting commercial barrier.
At the time of the November 2017 Bayer-Loxo partnership, larotrectinib was the most advanced selective TRK inhibitor with a 75% ORR across 17 tumor types (ASCO 2017), positioning it for the second tissue-agnostic FDA approval after Keytruda's MSI-H label. The closest competitor was Roche/Genentech's entrectinib (RXDX-101, acquired via Ignyta), a multikinase ROS1/ALK/TRK inhibitor with the strategic edge of CNS penetration—relevant because TRK fusions disproportionately affect CNS-involved pediatric tumors. Larotrectinib received FDA accelerated approval as Vitrakvi on November 26, 2018; Rozlytrek (entrectinib) followed in August 2019. LOXO-195 (selitrectinib) was positioned as a next-generation agent to address acquired resistance mutations to first-generation TRK inhibitors. The deal handed Bayer ex-US rights and a 50/50 US profit share, monetizing larotrectinib's launch ahead of Loxo's commercial build-out. Bayer subsequently took full global rights in early 2019 after Eli Lilly acquired Loxo for $8B, paying Lilly an additional payment to consolidate Vitrakvi. The deal validated tissue-agnostic precision oncology as a viable commercial model.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Loxo Oncology, Inc. (this deal) | 2017 | $1.6B | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2017 deals · Bayer AG deals · Oncology deals